Myomo, Inc. (MYO)
USD 4.64
(3.23%)
USD 4.64
(3.23%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 13.18 Million USD | 28.57% |
| 2022 | 10.25 Million USD | -0.57% |
| 2021 | 10.31 Million USD | 106.95% |
| 2020 | 4.98 Million USD | 70.64% |
| 2019 | 2.92 Million USD | 70.19% |
| 2018 | 1.71 Million USD | 62.86% |
| 2017 | 1.05 Million USD | 28.31% |
| 2016 | 821.11 Thousand USD | 84.41% |
| 2015 | 445.26 Thousand USD | -36.54% |
| 2014 | 701.67 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.29 Million USD | -25.95% |
| 2024 Q2 | 5.32 Million USD | 131.64% |
| 2023 FY | 13.18 Million USD | 28.57% |
| 2023 Q3 | 3.48 Million USD | -18.5% |
| 2023 Q1 | 2.3 Million USD | -12.18% |
| 2023 Q4 | 3.1 Million USD | -11.01% |
| 2023 Q2 | 4.28 Million USD | 85.52% |
| 2022 Q2 | 2.41 Million USD | -6.49% |
| 2022 Q1 | 2.57 Million USD | -17.43% |
| 2022 FY | 10.25 Million USD | -0.57% |
| 2022 Q4 | 2.62 Million USD | -0.36% |
| 2022 Q3 | 2.63 Million USD | 9.39% |
| 2021 Q4 | 3.12 Million USD | -4.62% |
| 2021 Q2 | 2.2 Million USD | 28.56% |
| 2021 Q1 | 1.71 Million USD | -38.42% |
| 2021 FY | 10.31 Million USD | 106.95% |
| 2021 Q3 | 3.27 Million USD | 48.62% |
| 2020 FY | 4.98 Million USD | 70.64% |
| 2020 Q2 | 439.72 Thousand USD | -36.22% |
| 2020 Q3 | 1.07 Million USD | 143.63% |
| 2020 Q4 | 2.78 Million USD | 159.72% |
| 2020 Q1 | 689.49 Thousand USD | -43.68% |
| 2019 Q4 | 1.22 Million USD | 196.99% |
| 2019 FY | 2.92 Million USD | 70.19% |
| 2019 Q3 | 412.24 Thousand USD | -34.53% |
| 2019 Q2 | 629.67 Thousand USD | -3.7% |
| 2019 Q1 | 653.87 Thousand USD | -1.44% |
| 2018 Q1 | 205.09 Thousand USD | -40.28% |
| 2018 Q4 | 663.39 Thousand USD | 59.7% |
| 2018 FY | 1.71 Million USD | 62.86% |
| 2018 Q2 | 431.92 Thousand USD | 110.59% |
| 2018 Q3 | 415.4 Thousand USD | -3.82% |
| 2017 Q2 | 208.04 Thousand USD | 51.13% |
| 2017 Q1 | 137.66 Thousand USD | -60.92% |
| 2017 Q3 | 364.44 Thousand USD | 75.18% |
| 2017 Q4 | 343.44 Thousand USD | -5.76% |
| 2017 FY | 1.05 Million USD | 28.31% |
| 2016 Q4 | 352.26 Thousand USD | 228.87% |
| 2016 Q2 | 203.88 Thousand USD | 29.16% |
| 2016 Q3 | 107.11 Thousand USD | -47.46% |
| 2016 Q1 | 157.85 Thousand USD | 73.1% |
| 2016 FY | 821.11 Thousand USD | 84.41% |
| 2015 FY | 445.26 Thousand USD | -36.54% |
| 2015 Q1 | 131.43 Thousand USD | 0.0% |
| 2015 Q4 | 91.19 Thousand USD | 0.0% |
| 2015 Q3 | 91.19 Thousand USD | -30.62% |
| 2015 Q2 | 131.43 Thousand USD | 0.0% |
| 2014 FY | 701.67 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott Laboratories | 22.13 Billion USD | 99.94% |
| Allurion Technologies Inc. | 41.49 Million USD | 68.233% |
| Artivion, Inc. | 229.17 Million USD | 94.248% |
| Avanos Medical, Inc. | 379.7 Million USD | 96.528% |
| Butterfly Network, Inc. | 16.85 Million USD | 21.794% |
| Butterfly Network, Inc. | 16.85 Million USD | 21.794% |
| Bio-Rad Laboratories, Inc. | 1.43 Billion USD | 99.079% |
| Boston Scientific Corporation | 9.89 Billion USD | 99.867% |
| CONMED Corporation | 643.06 Million USD | 97.95% |
| Edwards Lifesciences Corporation | 4.62 Billion USD | 99.715% |
| Paragon 28, Inc. | 172.79 Million USD | 92.371% |
| Glaukos Corporation | 239.13 Million USD | 94.487% |
| Globus Medical, Inc. | 1.02 Billion USD | 98.708% |
| Inspire Medical Systems, Inc. | 528.22 Million USD | 97.504% |
| Integer Holdings Corporation | 418.28 Million USD | 96.848% |
| Medtronic plc | 19.45 Billion USD | 99.932% |
| Nevro Corp. | 290.06 Million USD | 95.455% |
| Owlet, Inc. | 22.58 Million USD | 41.637% |
| Penumbra, Inc. | 682.64 Million USD | 98.069% |
| Vicarious Surgical Inc. | -1.85 Million USD | 811.024% |
| Smith & Nephew plc | 3.7 Billion USD | 99.644% |
| Sonendo, Inc. | 10.72 Million USD | -22.947% |
| STERIS plc | 2.23 Billion USD | 99.41% |
| Stryker Corporation | 13.05 Billion USD | 99.899% |
| Vapotherm, Inc. | 28.28 Million USD | 53.391% |
| Zimmer Biomet Holdings, Inc. | 5.31 Billion USD | 99.752% |